Lord’s Mark Industries Expands IVD Manufacturing in Vasai

Lord’s Mark Industries Ltd., a diversified Indian conglomerate, has significantly bolstered its healthcare division, LordsMed, with a specialized In-Vitro Diagnostics (IVD) manufacturing facility in Vasai, near Mumbai. The facility serves as a critical hub for the production of diagnostic instruments and reagents, aimed at meeting both domestic and international healthcare demands.

The expanded site is part of the company's broader push to enhance self-reliance in the medical technology sector. By transitioning from a trading-led business model to a manufacturing-focused operation, the firm is scaling its capacity to produce a wide array of high-risk and point-of-care diagnostic solutions, including biochemistry reagents, hematology kits, and serology testing tools.

Scaling Diagnostic Infrastructure

The Vasai manufacturing complex is equipped with state-of-the-art infrastructure compliant with ISO 13485:2016 and ISO 9001 standards, ensuring adherence to global quality benchmarks. This facility is central to the company's objective of facilitating over 1.7 crore diagnostic tests per month. Beyond standard diagnostic kits, the site is designed to accommodate complex R&D projects, including the production of AI-enabled point-of-care equipment developed in partnership with the Indian Institute of Technology (IIT) Bombay.

For the healthcare sector, this expansion addresses the need for cost-effective, indigenous diagnostic tools. "The launch of this facility draws inspiration from the government’s vision to make India a global medical device manufacturing hub," stated Sachidanand Upadhyay, Founder of Lord’s Mark Industries. He noted that the company is actively exploring Original Equipment Manufacturer (OEM) opportunities to further scale production and provide affordable diagnostics to hospitals, pathology labs, and government health centers.

Strategic Focus on "Make in India"

The facility plays a pivotal role in the company's backward integration strategy. By manufacturing essential diagnostic reagents and devices locally, the firm aims to reduce dependence on imports, which have historically been a bottleneck for the Indian diagnostic market.

Recent regulatory milestones have further bolstered the facility's operations. The company recently secured a manufacturing license for high-risk medical devices—specifically for HIV 1&2 self-tests—marking a significant step in its efforts to penetrate international markets across Africa, Latin America, and Europe. This export-oriented focus complements its strong domestic distribution network, which currently spans over 400 partners across India.

Official Sources Section

The operational details and manufacturing certifications were confirmed through LordsMed corporate disclosures and regulatory filings. The facility adheres to the Medical Devices Rules, 2017, as overseen by national regulatory bodies.

Quote Section

"According to officials at Lord’s Mark Industries, the Vasai facility lays the foundation for the company’s objective to become a global leader in IVD manufacturing, while simultaneously empowering rural and urban healthcare centers with accessible, reliable, and future-ready diagnostic solutions."

Why It Matters

For citizens, the increased production capacity means faster turnaround times for critical medical tests. For the diagnostic industry, this shift towards indigenous manufacturing helps stabilize supply chains and lowers the cost of healthcare delivery. Investors see the move as a strategic entry into the high-growth med-tech space, positioning the company as a key player in India’s efforts to improve public health infrastructure.

Key Facts at a Glance

• Facility Location: Vasai, Maharashtra.

• Manufacturing Capacity: Capable of facilitating over 1.7 crore diagnostic tests monthly.

• Product Scope: Biochemistry, hematology, serology, rapid testing kits, and AI-enabled diagnostic tools.

• Certifications: ISO 13485:2016 and ISO 9001.

• Strategic Goal: Reducing import dependence and expanding export presence in SAARC and global markets.

FAQ

What does the Vasai facility produce?

The facility produces a diversified range of IVD products, including biochemistry reagents, hematology analyzers, serology kits, and point-of-care testing devices.

How does this impact the Indian diagnostic market?

It increases the availability of locally manufactured diagnostic tools, reducing costs for pathology labs and hospitals while decreasing reliance on imported medical kits.

What is the role of IIT Bombay in this facility?

Lord’s Mark Industries collaborates with IIT Bombay to manufacture patented, AI-enabled point-of-care equipment, such as the "Shape DX" sickle cell testing device, at this site.

Source: LordsMed, Lord’s Mark Industries, Central Drugs Standard Control Organisation (CDSCO)